2nd gener drug switch case report feder offici investig bolar pharmaceut co possibl fraud connect approv gener version brand name anti depress drug mellaril knowledg offici said thursday food drug administr hous energi commerc oversight subcommitte look charg bolar fraudul submit brand name drug instead gener version test laboratori second incid report error reportedli correct feder offici said mistak correct time bolar gener drug ultim test approv gener drug market chemic thioridazin ident mellaril safe effect said stuff market real thing fda spokesman jeff nesbit said execut bolar copiagu n could reach comment second time week bolar one nation largest manufactur gener drug becom embroil broaden feder investig charg gener improperli test market fda announc monday withdraw approv bolar gener equival dyazid lead blood pressur drug investig bolar gener equival mellaril base 1982 letter pharmakinet laboratori inc baltimor told bolar believ bolar submit mellaril tablet instead gener equival determin equival pharmakinet job determin whether bolar gener chemic equival mellaril manufactur sandoz pharmaceut corp pharmakinet refus comment specif test bolar gener drug said statement seven year ago 1982 pharmakinet refus conduct bio equival studi tablet suppli compani pharmaceut manufactur refus base pharmakinet personnel visual inspect four batch test tablet caus compani offici question true identifi product commun suspicion manufactur pharmakinet said manufactur suppli tablet appear legitim test proceed fda ultim approv gener drug market probe uncov letter nesbit said fda discov pharmakinet 1982 letter bolar part investig alleg fraud briberi feder approv process low cost gener drug case appar drug switch come light current investig involv vitarin pharmaceut springfield n j voluntarili withdrawn gener version dyazid admit substitut sampl brand name drug approv process